Background: Anaemia occurs early in kidney disease which worsens with declining kidney function. Erythropoietin (EPO) is now widely used to correct anaemia including chronic kidney disease. Inflammation and infection increase hepcidin synthesis. The aim of the study is to determine the first dose effect of erythropoietin administration on anaemia status and hepcidin levels in chronic kidney disease patients undergoing haemodialysis. Materials and Methods: 25 patients were recruited (males n= 19, females n=6). Their mean age was 51.9 ± 8.0 years ranging between 33 and 63 years. Blood sampling was performed after three months of haemodialysis (pre-EPO) immediately followed by EPO injection and blood sampling 3 days thereafter. Haemoglobin, reticulocyte and hepcidin levels were including Pearson’s correlation were determined. Results and Discussion: Significant mild improvement in haemoglobin levels from mean 8.1 g/dL to 8.5 g/dL (P=<0.05) was seen and improved levels seen in only 76% of patients. Reticulocytes showed a mean rise from 1.02% to mean 1.33% (P=<0.01) and improved levels was seen in 80% of patients. Hepcidin levels showed a reduced trend from mean 72.5 ng. mL to 51.4 ng/mL but did not reach statistical significance (P=0.15). No change in hepcidin levels was seen in 64% of patients whilst reduced levels in 20% and further rise in 16% of patients. No significant correlation between the parameters studied was seen. Conclusion: The first EPO administration showed mild improved benefits in anaemia status but hepcidin levels improved in only 20% patients which need to be further determined after more EPO administration.